Evaluation of Serum Visfatin and Chemerin Levels in Diabetes Patients in Mosul City

ORIGINAL ARTICLE
Rana Ibrahim Khalil, Saria Naji Mohsin, Sura Hameed Nayyef

 
For citation: Khalil RI, Mohsin SN, Nayyef SH. Evaluation of Serum Visfatin and Chemerin Levels in Diabetes Patients in Mosul City. International Journal of Biomedicine. 2024;14(2):265-269. doi:10.21103/Article14(2)_OA4
 
Originally published June 5, 2024
 

Abstract: 

Background: Diabetes mellitus (DM) is a major public health concern worldwide. Although there are many possible causes of diabetes, the three most prevalent ones are insulin resistance, pancreatic cell damage, and insulin insufficiency. Visfatin, an adipocytokine with insulin-mimicking characteristics, and chemerin, an adipokine responsible for maintaining normal cholesterol and glucose levels, are linked to inflammation and immunological dysfunction in metabolic illnesses. Hence, in this study, we aimed to evaluate the possible association between type 2 diabetes mellitus (T2DM) and the adipokines visfatin and chemerin.
Methods and Results: This study was conducted at the Al-Salam Teaching Hospital in Mosul from December 1, 2022, to the end of June 2023. The study included 65 patients of both sexes with T2DM aged between 35 and 80. Twenty-five healthy individuals of both sexes were chosen for a control group. Visfatin and chemerin levels in the serum were measured using an ELISA kit (Koma biotech, ELISA, USA) per the manufacturer's instructions.
The levels of visfatin and chemerin in T2DM patients were significantly higher than in controls (1.478±0.631ng/ml and 158.768±36.941pg/ml vs. 0.538±0.151ng/ml and 71.272±12.994pg/ml, respectively, P=0.000 in both cases). The study showed no significant difference in the levels of chemerin and visfatin between females and males in T2DM patients. Among men, the visfatin levels were significantly higher in T2DM patients with diabetic retinopathy than in T2DM patients with such complications as cardiovascular disease and diabetic nephropathy. These features also occurred among women. Men and women with T2DM did not differ in the chemerin levels, depending on the nature of the diabetes complication.
Conclusion: T2DM patients are characterized by significantly higher visfatin and chemerin levels than healthy controls. No differences in the levels of these adipokines that depend on the gender of diabetic patients have been found.

Keywords: 
type 2 diabetes mellitus • visfatin • chemerin • insulin resistance
References: 
  1. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020 Nov;131:110708. doi: 10.1016/j.biopha.2020.110708. Epub 2020 Sep 11. PMID: 32927252.
  2. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275. doi: 10.3390/ijms21176275. PMID: 32872570; PMCID: PMC7503727.
  3. Lelis DF, Freitas DF, Machado AS, Crespo TS, Santos SHS. Angiotensin-(1-7), Adipokines and Inflammation. Metabolism. 2019 Jun;95:36-45. doi: 10.1016/j.metabol.2019.03.006. Epub 2019 Mar 21. PMID: 30905634.
  4. Hajri T, Gharib M, Kaul S, Karpeh MS Jr. Association between adipokines and critical illness outcomes. J Trauma Acute Care Surg. 2017 Sep;83(3):507-519. doi: 10.1097/TA.0000000000001610. PMID: 28697011.
  5. Ashraf H, Soltani D, Sobh-Rakhshankhah A, Jafari S, Boroumand MA, Goudarzi V, Vasheghani Farahani A, Masoudkabir F. Visfatin as marker of isolated coronary artery ectasia and its severity. Cytokine. 2019 Jan;113:216-220. doi: 10.1016/j.cyto.2018.07.007. Epub 2018 Jul 9. PMID: 30001864.
  6. Yu PL, Wang C, Li W, Zhang FX. Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis. Horm Metab Res. 2019 Apr;51(4):220-229. doi: 10.1055/a-0867-1333. Epub 2019 Apr 25. PMID: 31022738.
  7. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009 Aug;161(2):339-44. doi: 10.1530/EJE-09-0380. Epub 2009 Jun 4. PMID: 19497986.
  8. Susairaj P, Snehalatha C, Nanditha A, Satheesh K, Raghavan A, Vinitha R, Ramachandran A. Analysis of an Indian diabetes prevention programme on association of adipokines and a hepatokine with incident diabetes. Sci Rep. 2021 Oct 13;11(1):20327. doi: 10.1038/s41598-021-99784-x. PMID: 34645898; PMCID: PMC8514464.
  9. Sulaiman MM, Salih KN, Alazzawy MA. Role of Visfatin Chemerin with Type Two Diabetes Mellitus. Al-Kufa University Journal for Biology. 2019;11(1).
  10. Tabandeh MR, Taha AS, Addai Ali H, Razijalali M, Mohammadtaghvaei N. Type 2 Diabetes Mellitus Coincident with Clinical and Subclinical Thyroid Dysfunctions Results in Dysregulation of Circulating Chemerin, Resistin and Visfatin. Biomedicines. 2023 Jan 25;11(2):346. doi: 10.3390/biomedicines11020346. PMID: 36830883; PMCID: PMC9952980.
  11. Mir MM, Mir R, Alghamdi MAA, Wani JI, Sabah ZU, Jeelani M, Marakala V, Sohail SK, O'haj M, Alharthi MH, Alamri MMS. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. J Pers Med. 2022 May 1;12(5):735. doi: 10.3390/jpm12050735. PMID: 35629157; PMCID: PMC9143828.
  12. Akbarian N, Zarghami N, Mota A, Abediazar S, Abroon S, Mihanfar A, Amanzadeh M, Darbin A, Bannazadeh Baghi H, Rahmati-Yamchi M. Correlation Between Circulating Visfatin and Nitric Oxide Metabolites Levels in Patients With Diabetic Nephropathy. Iran J Kidney Dis. 2018 May;12(3):163-168. PMID: 29891746.
  13. Muayad Shukur Al Obaidi R. The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy. Arch Razi Inst. 2021 Sep 1;76(3):639-647. doi: 10.22092/ari.2021.355463.1688. PMID: 34824756; PMCID: PMC8605846.
  14. Wang Y, Yuan Y, Jiang H. Serum and vitreous levels of visfatin in patients with diabetic retinopathy. Med Sci Monit. 2014 Dec 19;20:2729-32. doi: 10.12659/MSM.891292. PMID: 25524991; PMCID: PMC4280054.
  15. Yasir M, Senthilkumar GP, Jayashree K, Ramesh Babu K, Vadivelan M, Palanivel C. Association of serum omentin-1, apelin and chemerin concentrations with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus patients. Arch Physiol Biochem. 2022 Apr;128(2):313-320. doi: 10.1080/13813455.2019.1680698. Epub 2019 Nov 5. PMID: 31686535.
  16. Kärberg K, Forbes A, Lember M. Visfatin and Subclinical Atherosclerosis in Type 2 Diabetes: Impact of Cardiovascular Drugs. Medicina (Kaunas). 2023 Jul 18;59(7):1324. doi: 10.3390/medicina59071324. PMID: 37512134; PMCID: PMC10386106.
  17. Gu P, Cheng M, Hui X, Lu B, Jiang W, Shi Z. Elevating circulation chemerin level is associated with endothelial dysfunction and early atherosclerotic changes in essential hypertensive patients. J Hypertens. 2015 Aug;33(8):1624-32. doi: 10.1097/HJH.0000000000000588. PMID: 26136068.
  18. Haybar H, Shahrabi S, Rezaeeyan H, Shirzad R, Saki N. Endothelial Cells: From Dysfunction Mechanism to Pharmacological Effect in Cardiovascular Disease. Cardiovasc Toxicol. 2019 Feb;19(1):13-22. doi: 10.1007/s12012-018-9493-8. PMID: 30506414.
  19. Macvanin MT, Rizzo M, Radovanovic J, Sonmez A, Paneni F, Isenovic ER. Role of Chemerin in Cardiovascular Diseases. Biomedicines. 2022 Nov 18;10(11):2970. doi: 10.3390/biomedicines10112970. PMID: 36428537; PMCID: PMC9687862.
  20. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC. Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci (Lond). 2014 Jul;127(2):111-22. doi: 10.1042/CS20130286. PMID: 24498891.
  21. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010 Mar 1;12(5):675-82. doi: 10.1089/ars.2009.2875. PMID: 19747062; PMCID: PMC2861539.
  22. Das S, Zhang E, Senapati P, Amaram V, Reddy MA, Stapleton K, Leung A, Lanting L, Wang M, Chen Z, Kato M, Oh HJ, Guo Q, Zhang X, Zhang B, Zhang H, Zhao Q, Wang W, Wu Y, Natarajan R. A Novel Angiotensin II-Induced Long Noncoding RNA Giver Regulates Oxidative Stress, Inflammation, and Proliferation in Vascular Smooth Muscle Cells. Circ Res. 2018 Dec 7;123(12):1298-1312. doi: 10.1161/CIRCRESAHA.118.313207. Erratum in: Circ Res. 2019 Dec 6;125(12):e112. PMID: 30566058; PMCID: PMC6309807.
  23. Cui L, Zhou Q, Zheng X, Sun B, Zhao S. Mitoquinone attenuates vascular calcification by suppressing oxidative stress and reducing apoptosis of vascular smooth muscle cells via the Keap1/Nrf2 pathway. Free Radic Biol Med. 2020 Dec;161:23-31. doi: 10.1016/j.freeradbiomed.2020.09.028. Epub 2020 Oct 2. PMID: 33011276.
  24. Dai L, Schurgers LJ, Shiels PG, Stenvinkel P. Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. Nephrol Dial Transplant. 2020 Mar 1;35(Suppl 2):ii31-ii37. doi: 10.1093/ndt/gfaa006. PMID: 32162665; PMCID: PMC7066546.
  25. Hart R, Greaves DR. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010 Sep 15;185(6):3728-39. doi: 10.4049/jimmunol.0902154. Epub 2010 Aug 18. PMID: 20720202. 
  26. Gasbarrino K, Mantzoros C, Gorgui J, Veinot JP, Lai C, Daskalopoulou SS. Circulating Chemerin Is Associated With Carotid Plaque Instability, Whereas Resistin Is Related to Cerebrovascular Symptomatology. Arterioscler Thromb Vasc Biol. 2016 Aug;36(8):1670-8. doi: 10.1161/ATVBAHA.115.306741. Epub 2016 Jun 16. PMID: 27312219.
  27. Zhou X, Tao Y, Chen Y, Xu W, Qian Z, Lu X. Serum Chemerin as a Novel Prognostic Indicator in Chronic Heart Failure. J Am Heart Assoc. 2019 Aug 6;8(15):e012091. doi: 10.1161/JAHA.119.012091. Epub 2019 Jul 23. PMID: 31333053; PMCID: PMC6761658.
  28. Behnoush AH, Shobeiri P, Bahiraie P, Amirkhani N, Khalaji A, Peiman S. Chemerin levels in chronic kidney disease: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Jan 25;14:1120774. doi: 10.3389/fendo.2023.1120774. PMID: 36761204; PMCID: PMC9907439.

Download Article
Received February 26, 2024.
Accepted April 4, 2024.
©2024 International Medical Research and Development Corporation.